Cabillic Florian, Hofman Paul, Ilie Marius, Peled Nir, Hochmair Maximilian, Dietel Manfred, Von Laffert Maximilian, Gosney John R, Lopez-Rios Fernando, Erb Gilles, Schalles Uwe, Barlesi Fabrice
Department of Cytogenetics and Cell Biology, CHU de Rennes, INSERM INRA, Université de Rennes 1, Université Bretagne Loire, Nutrition Metabolisms and Cancer, Rennes, France.
Laboratory of Clinical and Experimental Pathology and Hospital-Integrated Biobank, Nice, France.
ESMO Open. 2018 Sep 17;3(6):e000419. doi: 10.1136/esmoopen-2018-000419. eCollection 2018.
Lung cancer is the most common cancer worldwide. Latest guidelines from the College of American Pathologist and the European society of medical oncologists indicate anaplastic lymphoma kinase (ALK) rearrangement testing is standard practice. Historically, diagnostics for ALK used fluorescence in situ hybridisation (FISH); however, immunohistochemical (IHC) assays are becoming common practice. Unfortunately, recent assessment of current practice indicated that not all patients who should be tested for ALK translocation are undergoing ALK testing.
From a series of European and Israeli labs, we collected patients with discordant IHC and FISH testing, which were subsequently treated with ALK-targeted therapy, for discussion of the question, to treat or not to treat?
Our study may support ALK IHC testing as a better predictor of response to targeted therapy provided that the labs implement controlled preanalytical procedures, use correct clone, run protocols on automated staining platforms and validate using external quality assessments.
肺癌是全球最常见的癌症。美国病理学家学会和欧洲医学肿瘤学家学会的最新指南表明，间变性淋巴瘤激酶（ALK）重排检测是标准做法。从历史上看，ALK的诊断使用荧光原位杂交（FISH）；然而，免疫组织化学（IHC）检测正变得越来越普遍。不幸的是，最近对当前实践的评估表明，并非所有应该进行ALK易位检测的患者都在接受ALK检测。
我们从一系列欧洲和以色列实验室收集了免疫组化和FISH检测结果不一致的患者，这些患者随后接受了ALK靶向治疗，以讨论治疗与否的问题。
我们的研究可能支持将ALK免疫组化检测作为对靶向治疗反应的更好预测指标，前提是实验室实施受控的分析前程序，使用正确的克隆，在自动染色平台上运行方案并通过外部质量评估进行验证。
Zotero 插件